CN101600725B - 制备呋喃核糖基嘧啶核苷 - Google Patents

制备呋喃核糖基嘧啶核苷 Download PDF

Info

Publication number
CN101600725B
CN101600725B CN200780037855.XA CN200780037855A CN101600725B CN 101600725 B CN101600725 B CN 101600725B CN 200780037855 A CN200780037855 A CN 200780037855A CN 101600725 B CN101600725 B CN 101600725B
Authority
CN
China
Prior art keywords
aryl
formula
methyl
fluoro
tetrahydrochysene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200780037855.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN101600725A (zh
Inventor
S·D·阿克斯特
K·萨尔曼
J·瓦伊塔尔
J·朱
B·罗斯
S·拉卡康达
金庆武
牛炳权
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmasset Ltd
F Hoffmann La Roche AG
Gilead Pharmasset LLC
Original Assignee
Pharmasset Ltd
F Hoffmann La Roche AG
Gilead Pharmasset LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmasset Ltd, F Hoffmann La Roche AG, Gilead Pharmasset LLC filed Critical Pharmasset Ltd
Publication of CN101600725A publication Critical patent/CN101600725A/zh
Application granted granted Critical
Publication of CN101600725B publication Critical patent/CN101600725B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/02—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN200780037855.XA 2006-10-10 2007-10-05 制备呋喃核糖基嘧啶核苷 Active CN101600725B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85096206P 2006-10-10 2006-10-10
US60/850,962 2006-10-10
PCT/US2007/021548 WO2008045419A1 (en) 2006-10-10 2007-10-05 Preparation of nucleosides ribofuranosyl pyrimidines

Publications (2)

Publication Number Publication Date
CN101600725A CN101600725A (zh) 2009-12-09
CN101600725B true CN101600725B (zh) 2014-11-26

Family

ID=39111500

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200780037855.XA Active CN101600725B (zh) 2006-10-10 2007-10-05 制备呋喃核糖基嘧啶核苷

Country Status (18)

Country Link
US (2) US8912321B2 (enExample)
EP (1) EP2084174B1 (enExample)
JP (1) JP5252459B2 (enExample)
KR (1) KR101057239B1 (enExample)
CN (1) CN101600725B (enExample)
AU (1) AU2007307057B2 (enExample)
BR (1) BRPI0719174A2 (enExample)
CA (1) CA2666098C (enExample)
DK (1) DK2084174T3 (enExample)
ES (1) ES2429290T3 (enExample)
GT (1) GT200900080A (enExample)
IL (1) IL198086A (enExample)
MX (1) MX2009003795A (enExample)
PL (1) PL2084174T3 (enExample)
PT (1) PT2084174E (enExample)
RU (1) RU2421461C2 (enExample)
SI (1) SI2084174T1 (enExample)
WO (1) WO2008045419A1 (enExample)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
ES2624353T3 (es) 2002-11-15 2017-07-13 Idenix Pharmaceuticals Llc 2'-Metil nucleósidos en combinación con interferón y mutación de Flaviviridae
EP4032897B1 (en) 2003-05-30 2025-01-29 Gilead Pharmasset LLC Modified fluorinated nucleoside analogues
WO2006031725A2 (en) * 2004-09-14 2006-03-23 Pharmasset, Inc. Preparation of 2'­fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
CN101057259B (zh) 2004-11-16 2010-11-03 汤姆森许可贸易公司 基于预计算的变换系数的胶片颗粒仿真方法
CN101138247B (zh) 2004-11-16 2010-05-26 汤姆森特许公司 位精度仿真的胶片颗粒补充增强信息消息插入方法及系统
MX2007005651A (es) 2004-11-17 2007-06-05 Thomson Licensing Metodo de simulacion de grano de pelicula exacto de bits con base en coeficientes transformados pre-computados.
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US10715834B2 (en) 2007-05-10 2020-07-14 Interdigital Vc Holdings, Inc. Film grain simulation based on pre-computed transform coefficients
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
SG172359A1 (en) 2008-12-23 2011-07-28 Pharmasset Inc Nucleoside phosphoramidates
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
NZ593647A (en) * 2008-12-23 2013-08-30 Gilead Pharmasset Llc Synthesis of purine nucleosides
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
TW201136945A (en) 2010-03-31 2011-11-01 Pharmasset Inc Purine nucleoside phosphoramidate
JP2013527145A (ja) 2010-03-31 2013-06-27 ギリード・ファーマセット・エルエルシー リン含有活性化剤の立体選択的合成
JP5716500B2 (ja) 2010-06-03 2015-05-13 セントラル硝子株式会社 （２Ｒ）−２−フルオロ−２−Ｃ−メチル−Ｄ−リボノ−γ−ラクトン類前駆体の製造方法
PT3042910T (pt) 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-espiro-nucleósidos para utilização na terapia da hepatite c
US9243025B2 (en) 2011-03-31 2016-01-26 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections
WO2013039920A1 (en) 2011-09-12 2013-03-21 Idenix Pharmaceuticals, Inc. Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
CA2840242C (en) 2011-09-16 2019-03-26 Gilead Sciences, Inc. Methods for treating hcv
WO2013056046A1 (en) 2011-10-14 2013-04-18 Idenix Pharmaceuticals, Inc. Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
PT107894A (pt) 2011-10-21 2014-10-31 Abbvie Inc Métodos para o tratamento de hcv compreendendo pelo menos dois agentes antivirais de actuação directa, ribavirina, mas não interferão.
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
GB2515942A (en) 2011-10-21 2015-01-07 Abbvie Inc Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
EP2852605B1 (en) 2012-05-22 2018-01-31 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphate prodrugs for hcv infection
BR112014029115A8 (pt) 2012-05-22 2018-04-03 Idenix Pharmaceuticals Inc Composto, composição farmacêutica, e, uso de um composto ou composição
EP2852604B1 (en) 2012-05-22 2017-04-12 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphoramidate prodrugs for hcv infection
MX2014014323A (es) 2012-05-25 2015-02-12 Janssen R & D Ireland Nucleosidos de espirooxetano de uracilo.
HK1207384A1 (en) * 2012-05-29 2016-01-29 F. Hoffmann-La Roche Ag Process for the preparation of 2-deoxy-2-fluoro-2-methyl-d-ribofuranosyl nucleoside compounds
CN103450148B (zh) * 2012-06-04 2018-06-12 浙江九洲药业股份有限公司 一种五元环硫酸酯化合物的合成方法
WO2014052638A1 (en) 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
CN104936970A (zh) 2012-10-08 2015-09-23 埃迪尼克斯医药公司 用于hcv感染的2′-氯核苷类似物
CN103724301A (zh) 2012-10-10 2014-04-16 上海特化医药科技有限公司 (2r)-2-脱氧-2,2-二取代-1,4-核糖内酯及其制备方法和用途
US10723754B2 (en) 2012-10-22 2020-07-28 Idenix Pharmaceuticals Llc 2′,4′-bridged nucleosides for HCV infection
WO2014099941A1 (en) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
CN103012386B (zh) * 2012-12-26 2015-04-01 浙江普洛得邦制药有限公司 一种五元环状硫酸酯的制备方法
KR20200060782A (ko) 2013-01-31 2020-06-01 길리애드 파마셋 엘엘씨 두 항바이러스 화합물의 병용 제형물
US10034893B2 (en) 2013-02-01 2018-07-31 Enanta Pharmaceuticals, Inc. 5, 6-D2 uridine nucleoside/tide derivatives
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
WO2014160484A1 (en) 2013-03-13 2014-10-02 Idenix Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
WO2014165542A1 (en) 2013-04-01 2014-10-09 Idenix Pharmaceuticals, Inc. 2',4'-fluoro nucleosides for the treatment of hcv
EP3004130B1 (en) 2013-06-05 2019-08-07 Idenix Pharmaceuticals LLC. 1',4'-thio nucleosides for the treatment of hcv
EP3027636B1 (en) 2013-08-01 2022-01-05 Idenix Pharmaceuticals LLC D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
EP3650014B1 (en) 2013-08-27 2021-10-06 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
CN104447923B (zh) * 2013-09-23 2018-03-30 中国药科大学 2’‑脱氧‑2’‑氟‑2’‑甲基核苷衍生物及其制备方法与在制药中的用途
EP3131914B1 (en) 2014-04-16 2023-05-10 Idenix Pharmaceuticals LLC 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
WO2016033164A1 (en) 2014-08-26 2016-03-03 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
WO2016042576A1 (en) 2014-09-16 2016-03-24 Cadila Healthcare Limited Co-crystal of sofosbuvir and amino acid and process for preparation thereof
CN104744539A (zh) * 2014-09-19 2015-07-01 上海皓元生物医药科技有限公司 一种(2’r)-2’-脱氧-2’-氟-2’-甲基脲苷的合成方法
CN104327138B (zh) * 2014-10-21 2017-05-10 齐鲁制药有限公司 Psi‑7977中间体化合物的制备方法
WO2016073756A1 (en) 2014-11-06 2016-05-12 Enanta Pharmaceuticals, Inc. Deuterated nucleoside/tide derivatives
US9732110B2 (en) 2014-12-05 2017-08-15 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
CN104610404B (zh) * 2015-01-16 2016-04-06 南通常佑药业科技有限公司 一种呋喃核糖磷酸酯衍生物的制备方法
MY190867A (en) 2015-03-06 2022-05-13 Atea Pharmaceuticals Inc ? -d-2'-deoxy-2'-?-fluoro-2'- ? -c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
CN104829672B (zh) * 2015-05-19 2018-03-13 江苏福瑞生物医药有限公司 一种药物中间体的合成方法
CN105061535A (zh) * 2015-09-02 2015-11-18 江苏科本医药化学有限公司 一种索非布韦中间体的合成方法
CN106554333B (zh) * 2015-09-29 2018-11-30 江苏福瑞生物医药有限公司 一种药物中间体的合成方法
CN106608896B (zh) * 2015-10-26 2019-08-27 江苏福瑞康泰药业有限公司 一种药物中间体的合成方法
CN105418547A (zh) * 2015-11-17 2016-03-23 海门慧聚药业有限公司 索非布韦关键中间体的制备
CN105503983B (zh) * 2015-12-17 2019-06-28 江苏阿尔法药业有限公司 索菲布韦中间体及其衍生物的制备方法
CN105566422B (zh) * 2015-12-29 2019-06-25 江苏阿尔法药业有限公司 索菲布韦中间体或其衍生物的制备方法
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
US10711029B2 (en) 2016-07-14 2020-07-14 Atea Pharmaceuticals, Inc. Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
US10239910B2 (en) 2016-07-20 2019-03-26 Optimus Drugs (P) Limited Process for the preparation of sofosbuvir
PL3512863T3 (pl) 2016-09-07 2022-04-04 Atea Pharmaceuticals, Inc. 2'-Podstawione-N6-podstawione nukleotydy purynowe do leczenia zakażeń wirusem RNA
IL295609B2 (en) 2017-02-01 2023-11-01 Atea Pharmaceuticals Inc Nucleotide hemisulfate salt for the treatment of hepatitis C virus
CN106810515A (zh) * 2017-02-06 2017-06-09 抚州市星辰药业有限公司 一种合成索非布韦的中间体化合物及其合成方法
CN109422789A (zh) * 2017-08-28 2019-03-05 常州制药厂有限公司 一种索非布韦的制备工艺改进方法
CN112351799A (zh) 2018-04-10 2021-02-09 阿堤亚制药公司 具有硬化的hcv感染患者的治疗
CN108675984A (zh) * 2018-06-22 2018-10-19 江苏阿尔法药业有限公司 索非布韦中间体的制备方法
CN111606961A (zh) * 2019-02-26 2020-09-01 顾世海 一种(2’r)-2’-脱氧-2’-氟-2’-甲基脲苷的工艺生产方法
CN111040010A (zh) * 2019-12-23 2020-04-21 上海红蓝医药科技有限公司 一种索非布韦中间体的合成方法
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
BR112023026356A2 (pt) 2021-06-17 2024-03-05 Atea Pharmaceuticals Inc Método para tratar vírus da hepatite c ou uma condição resultante de uma infecção por hepatite c, combinação, uso da combinação, composição farmacêutica, e, kit para o tratamento de vírus da hepatite c

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0136693A2 (en) * 1983-10-03 1985-04-10 Takeda Chemical Industries, Ltd. Production of cytidine derivatives
WO2006012440A2 (en) * 2004-07-21 2006-02-02 Pharmasset, Inc. Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives
WO2006031725A2 (en) * 2004-09-14 2006-03-23 Pharmasset, Inc. Preparation of 2'­fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2559917B2 (ja) * 1990-06-15 1996-12-04 三共株式会社 ピリミジンヌクレオシド誘導体
US5637688A (en) * 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
IL138037A0 (en) 1998-02-25 2001-10-31 Univ Emory 2'-fluoronucleosides
AU6388900A (en) 1999-07-30 2001-02-19 Abbott Gmbh & Co. Kg 2-pyrazolin-5-ones
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
CZ301182B6 (cs) 2000-05-26 2009-12-02 Idenix (Cayman) Limited Použití nukleosidových derivátu pro výrobu farmaceutických prostredku pro lécení infekcí vyvolaných flaviviry a pestiviry
US7105499B2 (en) 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
HUP0400726A3 (en) 2001-01-22 2007-05-29 Merck & Co Inc Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2003026589A2 (en) 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
WO2004002422A2 (en) 2002-06-28 2004-01-08 Idenix (Cayman) Limited 2’-c-methyl-3’-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
TW200500375A (en) 2002-06-28 2005-01-01 Idenix Cayman Ltd Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
ES2624353T3 (es) 2002-11-15 2017-07-13 Idenix Pharmaceuticals Llc 2'-Metil nucleósidos en combinación con interferón y mutación de Flaviviridae
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
EP4032897B1 (en) 2003-05-30 2025-01-29 Gilead Pharmasset LLC Modified fluorinated nucleoside analogues
ATE478886T1 (de) 2003-07-25 2010-09-15 Idenix Pharmaceuticals Inc Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c
CA2537114C (en) 2003-08-27 2012-10-02 Biota, Inc. Tricyclic nucleosides or nucleotides as therapeutic agents
CA2565013C (en) * 2004-04-30 2013-01-08 Daiichi Pharmaceutical Co., Ltd. Method for producing pentacyclic taxans

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0136693A2 (en) * 1983-10-03 1985-04-10 Takeda Chemical Industries, Ltd. Production of cytidine derivatives
WO2006012440A2 (en) * 2004-07-21 2006-02-02 Pharmasset, Inc. Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives
WO2006031725A2 (en) * 2004-09-14 2006-03-23 Pharmasset, Inc. Preparation of 2'­fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives

Also Published As

Publication number Publication date
ES2429290T3 (es) 2013-11-14
IL198086A0 (en) 2009-12-24
EP2084174B1 (en) 2013-07-31
HK1133889A1 (en) 2010-04-09
BRPI0719174A2 (pt) 2017-06-13
US8912321B2 (en) 2014-12-16
PT2084174E (pt) 2013-10-08
KR101057239B1 (ko) 2011-08-16
GT200900080A (es) 2012-04-10
US20080139802A1 (en) 2008-06-12
MX2009003795A (es) 2009-06-18
SI2084174T1 (sl) 2013-10-30
KR20090060460A (ko) 2009-06-12
JP2010505954A (ja) 2010-02-25
RU2421461C2 (ru) 2011-06-20
IL198086A (en) 2012-03-29
CN101600725A (zh) 2009-12-09
CA2666098A1 (en) 2008-04-17
RU2009117396A (ru) 2010-11-20
AU2007307057B2 (en) 2011-09-15
PL2084174T3 (pl) 2013-12-31
DK2084174T3 (da) 2013-11-04
US20100056770A1 (en) 2010-03-04
AU2007307057A1 (en) 2008-04-17
CA2666098C (en) 2012-09-25
WO2008045419A1 (en) 2008-04-17
EP2084174A1 (en) 2009-08-05
JP5252459B2 (ja) 2013-07-31

Similar Documents

Publication Publication Date Title
CN101600725B (zh) 制备呋喃核糖基嘧啶核苷
JP2010505954A5 (enExample)
EP0342203B1 (en) 2',3' dideoxyribofuranoxide derivatives
CN100335492C (zh) 生产3’－核苷前体药物的方法
JP2010533659A (ja) ２’−フルオロ−４’−置換−ヌクレオシド類似体、その製造方法及び使用
KR20170073649A (ko) 치환된 뉴클레오시드 유사체의 제조 방법
CN104379591A (zh) 用于制备2-脱氧-2-氟-2-甲基-d-呋喃核糖基核苷化合物的方法
CN113929724A (zh) 一种核苷类化合物及其药物组合物和用途
JP2023011699A (ja) ３位置換５－アミノ－６Ｈ－チアゾロ［４，５－ｄ］ピリミジン－２，７－ジオン化合物の製造法
US9624258B2 (en) Polymorph of regadenoson
US9580457B2 (en) Process for the preparation of (1-{9-[(4S, 2R, 3R, 5R)-3, 4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl)-6-aminopurin-2-yl}pyrazole-4-yl)-N-methylcarboxamide
US8193354B2 (en) Process for preparation of Gemcitabine hydrochloride
KR102124470B1 (ko) 신규 혈관누출 차단제의 고수율 제조방법
CN101646685B (zh) 合成ib-meca的方法
JP2009526782A (ja) ゲムシタビンおよび関連中間体の製造方法
CN102775450A (zh) 一种1,6-脱水-2-叠氮-2-脱氧-β-D-吡喃葡萄糖的制备方法
WO2010036904A2 (en) Preparation of valganciclovir and its salts
JP7423533B2 (ja) 配糖体化合物の製造方法
HK1133889B (en) Preparation of nucleosides ribofuranosyl pyrimidines
Dao et al. Synthesis of 8-methyl-2-O-methyl-3, 5-O-(1-methyl ethylidene)-6, 7, 8, 9-tetradeoxy-D-gulo-6-nonenonic acid (6E)--lactone
CN112375076A (zh) 合成卡格列净的新方法
CN111592531A (zh) 福瑞塞替的制备方法
WO2009082844A1 (fr) Dérivé hydroxyle de la capécitabine, ses procédés de préparation et ses utilisations pour préparer la capécitabine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: American California

Applicant after: Pharmasset Inc.

Applicant after: Hoffmann La Roche

Address before: new jersey

Applicant before: Pharmasset Ltd.

Applicant before: Hoffmann La Roche

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: PHARMASSET INC. TO: GILEAD PHARMACEUTICALS LTD.

C14 Grant of patent or utility model
GR01 Patent grant